|
Pyadushkina E.A., Goryaynov S.V., Omelyanovsky V.V., Avxentyeva M.V., Rebrova O.Yu.
Clinicoeconomic analysis of the use of maraviroc versus other reserve drugs in patients who have experienced antiretroviral therapy for HIV infection
|
№5 / 2013
|
|
Volkova S.B., Podymova A.S.
Experience with the HIV protease inhibitor fosamprenavir in russian practice
|
№4 / 2013
|
|
Sundukov A.V., Gafurov Yu.T., Evsyukov O. A.
Clinical and laboratory features of abnormalities in the cervix uteri, external genitals, and vagina in HIV-infected patients
|
№4 / 2013
|
|
Pyadushkina E.A., Andreeva N.S., Omelyanovsky V.V., Avxentyeva M.V., Rebrova O.Yu.
Сlinicoeconomic analysis of the use of kivexa in the first-line antiretroviral therapy of HIV infection in the Russian Federation
|
№3 / 2013
|
|
Kravchenko A.V., Kanestri V.G.
Use of the fusion inhibitor enfuvirtide in antiretroviral therapy regimens for HIV-infected patients
|
№1 / 2013
|
|
Kanestri V.G.
The novel HIV non-nucleoside reverse transcriptase inhibitor rilpivirine: a review of international clinical trials
|
№3 / 2012
|
|
Kravchenko A.V., Kanestri V.G.
The HIV nucleoside reverse transcriptase inhibitors abacavir and lamivudine in first-line antiretroviral therapy regimens
|
№2 / 2011
|
|
Kravchenko A.V., Zimina V.N., Viktorova I.B., Sitdykova Yu.R.
Manifestation of immune reconstitution inflammatory syndrome during antiretroviral therapy in patients with HIV infection
|
№1 / 2011
|
Русский
